Therapeutic antibodies under development for SARS‐CoV‐2
Open Access
- 12 July 2021
- Vol. 3 (2), 20200178
- https://doi.org/10.1002/viw.20200178
Abstract
The world is experiencing one of the most difficult moments in history with COVID-19, which has rapidly developed into a worldwide pandemic with a significant health and economic burden. Efforts to fight the virus, including prevention and treatment, have never stopped. However, no specific drugs or treatments have yet been found. Antibody drugs have never been absent in epidemics such as SARS, MERS, HIV, Ebola, and so on in the past two decades. At present, while research on the SARS-CoV-2 vaccine is in full swing, antibody drugs are also receiving widespread attention. Several antibody drugs have successfully entered clinical trials and achieved impressive therapeutic effects. Here, we summarize the therapeutic antibodies against SARS-CoV-2, as well as the research using ACE2 recombinant protein or ACE2-Ig fusion protein.Keywords
Funding Information
- National Natural Science Foundation of China (82041012, 81773261, 31970882, 81903140, 81602690)
This publication has 51 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- COVID-19: combining antiviral and anti-inflammatory treatmentsThe Lancet Infectious Diseases, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Traditional Chinese medicine for COVID-19 treatmentPharmacological Research, 2020
- Van der Waals thin films of WTe2 for natural hyperbolic plasmonic surfacesNature Communications, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Entry of Human Coronavirus NL63 into the CellJournal of Virology, 2018
- Surface vimentin is critical for the cell entry of SARS-CoVJournal of Biomedical Science, 2016